The COVID-19 shots made by China’s state-owned Sinopharm and Johnson & Johnson, as well as the Sputnik vaccine developed by Russia, were found in a study to produce little or no antibodies against Omicron, the new version of the vaccine- As evidence of developed abilities. Mt.
Researchers from the University of Washington and Swiss drugmaker Humabs Biomed SA analyzed the efficacy of six vaccines against the highly infectious and most commonly mutated COVID variant. Only three of the 13 people who took both doses of Sinopharm’s shot showed neutralizing antibodies against Omicron. For J&J, this metric fell to one in 12 samples. None of the 11 people who were fully vaccinated with Sputnik produced such antibodies.
The study, which is published as a pre-print and has yet to be peer-reviewed, also found that the lowest reduction in protective antibodies came from a combination of two doses of a prior infection and Pfizer Inc.’s mRNA shots . Antibody levels fell five-fold in this sub-group of people, compared to 44-fold for those who took both shots from Pfizer but did not have a history of COVID infection.
Russia’s Gamalya Center, which developed Sputnik, said in a statement that the serum samples used in the study were not representative and that conclusions should not be drawn about the efficacy of the vaccine against Omicron.
A preliminary study has shown that Sputnik is expected to provide a strong defense against severe cases of the variant, Gamalea’s partner, the Russian Direct Investment Fund, said in a statement on Friday.
Emerging research that some of the most widely used vaccines provide only a partial shield against omicrons has worried governments are implementing travel restrictions and booster shot campaigns to prevent further virus waves and economy-disrupting lockdowns. Bidding to speed up The new variant, which infects 70 times faster than the deadly Delta, has rapidly spread to 77 countries, less than a month after it was first detected in southern Africa.
The latest study found that people vaccinated with two doses of the Pfizer-BioNtech and Moderna Ink shots also produced fewer antibodies. People with the viral vector vaccine – developed by the University of Oxford and AstraZeneca plc – have a finding in line with other studies that have suffered a loss of protection.
improve security
Studies conducted earlier this week showed that Sinovac Biotech Ltd.’s vaccine – the Pfizer-BioNtech shot as well as the most widely used vaccine in the world – was sufficient against Omicron and boosters even after two doses. Does not provide antibodies. Protection needs improvement.
This has left scientists and public health officials scrambling for ways to increase protection against the new variant, including rolling out the third dose three months after the second, mixing and matching different vaccines, and introducing a new generation of omicron-targeted vaccines. Involves developing shots.
Still, studies examining antibody levels are looking at just one arm of the immune response that protects people from infection. The other arm of the immune response is cell mediated immunity – known as a T-cell response – that can protect people from serious illness and death. Research is still ongoing into how T-cells respond to omicrons.
Never miss a story! Stay connected and informed with Mint.
download
Our App Now!!
,